This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY sees strong order momentum, APAC growth and CyberKnife demand, but soft product sales and regional headwinds cloud near-term gains.
SYK Partners With Siemens Healthineers to Boost Stroke, Aneurysm Care
by Zacks Equity Research
Stryker teams with Siemens Healthineers to develop a robotic ecosystem aimed at advancing stroke and aneurysm care.
Avanos Medical Buys Nexus Medical to Bolster Critical Care Portfolio
by Zacks Equity Research
AVNS acquires Nexus Medical, adding its TKO connector to expand critical care offerings and drive immediate revenue and earnings growth.
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
by Zacks Equity Research
ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.
BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care
by Zacks Equity Research
BrainsWay shares surge after the FDA cleared its accelerated Deep TMS protocol, offering faster depression treatment with strong clinical results.
CAH Strengthens Distribution With New Consumer Health Logistics Hub
by Zacks Equity Research
Cardinal Health opens a 350,000-square-foot Consumer Health Logistics Center in Ohio, strengthening its pharmaceutical supply chain and advancing its multiyear infrastructure expansion strategy.
GEHC Expands Women's Health Portfolio With AI-Enabled Voluson
by Zacks Equity Research
GE HealthCare debuts AI-powered Voluson Performance ultrasound systems, enhancing women's health imaging with faster, smarter diagnostics.
ISRG Stock Dips Despite Introducing Real-Time Insights on da Vinci 5
by Zacks Equity Research
Intuitive Surgical unveils real-time surgical insights on its da Vinci 5, enhancing precision, safety, and efficiency with advanced software features.
GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio
by Zacks Equity Research
GE HealthCare moves to strengthen its neurology portfolio by acquiring icometrix, aiming to integrate AI-driven brain MRI solutions into its imaging platforms.
MMSI Stock Falls Despite CE Mark Win for Embosphere in Knee OA Care
by Zacks Equity Research
Merit Medical secures CE Mark for Embosphere, expanding its use in knee osteoarthritis treatment with a minimally invasive alternative.
5 Must-Buy Laggards of 2025 With Double-Digit Short-Term Price Upside
by Nalak Das
Five lagging stocks, namely, AIZ, DOCU, DUOL, WST and ZBRA, now offer strong short-term upside despite 2025's AI-driven rally.
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
by Zacks Equity Research
PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
by Zacks Equity Research
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
by Zacks Equity Research
WST rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.
Reasons to Retain Avanos Medical Stock in Your Portfolio Now
by Zacks Equity Research
AVNS's solid Q2 performance, strong product demand, and strategic transformation support growth amid tariff and FX headwinds.
Dentsply Sirona Retains Wellspect Following Strategic Review
by Zacks Equity Research
XRAY will keep its Wellspect unit, betting on its strong cash flows and $2B market to deliver greater long-term shareholder value.
Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System
by Zacks Equity Research
MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.
Lifeward Achieves European Approval for Latest ReWalk Exoskeleton
by Zacks Equity Research
LFWD secures CE mark for its ReWalk 7 Personal Exoskeleton, unlocking new European sales potential with advanced features.
Cardinal Health Expands At-Home Solutions With New Texas Facility
by Zacks Equity Research
CAH announces the opening of a new distribution center in Texas, which is likely to support its at-Home Solutions business.
GEHC Stock Gains Following Launch of Revolution Vibe CT Imaging System
by Zacks Equity Research
GE HealthCare's FDA-cleared Revolution Vibe CT promises faster, AI-driven cardiac imaging with improved clarity, boosting efficiency and patient comfort.
PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq
by Zacks Equity Research
PacBio collaborates with EpiCypher to integrate Fiber-Seq and HiFi sequencing, advancing single-molecule epigenomics with new chromatin mapping tools.
Here's Why You Should Hold Cencora Stock in Your Portfolio Now
by Zacks Equity Research
COR gains from strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose risks.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL's strong Q2 results, innovation pipeline, and high-tech growth drivers support its long-term expansion despite macro headwinds.
HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
HQY's Q2 results reflect EPS growth of 25.6% year over year, revenue growth of 8.6% and a 12% increase in HSA. The company also updates its fiscal 2026 guidance.
STXS Launches First U.S. Robotic HD Mapping With MAGiC Sweep
by Zacks Equity Research
Stereotaxis debuts MAGiC Sweep, the first U.S. robotic HD mapping catheter, marking a breakthrough in cardiac arrhythmia diagnosis and treatment.